<span class="entry-title-primary">Global Liraglutide Market Analysis by Region and Future Trends till 2024</span> <span class="entry-subtitle">Global Liraglutide Market Research Growth - 2024</span><span class="rating-result after_title mr-filter rating-result-8877">			<span class="no-rating-results-text">No ratings yet.</span>		</span>
Liraglutide market
Global Liraglutide Market Analysis by Region and Future Trends till 2024 Global Liraglutide Market Research Growth - 2024

Liraglutide Market 2019-2024

Liraglutide NN2211 is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.

The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method.
In these patents, accounting for Europe is the largest, followed by North America, and finally Asia.

The application of Liraglutide 

Liraglutide for the treatment of type 2 diabetes mellitus
Liraglutide 1.2 mg daily in triple therapy regimens in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in Type 2 diabetes: the management of type 2 diabetes

Liraglutide 1.2 mg daily in dual therapy regimens in combination with metformin or a sulphonylurea is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 DPP-4 inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.

Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes.

The Committee concluded that the evidence provided was not robust enough to allow it to recommend liraglutide as a cost-effective alternative to either thiazolidinediones or DPP-4 inhibitors as a triple therapy regimen, however it believes liraglutide is a cost-effective treatment option relative to exenatide.

Taking into account the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes.

The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop.

Access Full Report with TOC @ https://www.planetmarketreports.com/reports/liraglutide-market-2019-2024

According to this study, over the next five years the Liraglutide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share sales and revenue of key companies in Liraglutide business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide market by product type, application, key manufacturers and key regions and countries.

This study considers the Liraglutide value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.


Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.

Drug Store

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

United States
Southeast Asia
Middle East & Africa
South Africa
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

HEC Pharm
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Liraglutide consumption value & volume by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Liraglutide market by identifying its various subsegments.

Focuses on the key global Liraglutide manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Liraglutide with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industry-specific challenges and risks .

To project the consumption of Liraglutide submarkets, with respect to key regions along with their respective key countries .
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Customizations available

In case of any queries or customization requirements please connect with our sales team sales@planetmarketreports.com, which will ensure that your requirements are met.

Browse a Free Sample Report @ https://www.planetmarketreports.com/report-sample/liraglutide-market-2019-2024


About Us:

Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision making process. We have huge database of market research reports & company profiles across globe.  We associated with global market research a publisher who has a wide range of research specialists & industry experts which provides you deeper penetration of market research industry.

We have statistical surveying reports from number of top publishers and update our reports collections on daily basis with most recent research data to furnish our customers with the moment online access to our database. With access to this database, our customers will be able to benefit from expert insights on worldwide businesses, items, and market patterns. We help you in your buy choice by mapping your data needs with our immense accumulation of reports.

Contact US:- 

Name: Jennifer Daniel 

Email-Id: sales@planetmarketreports.com

US: +1-716-2260907

UK: +447441952057

Organization: Planet Market Reports

Please rate this

Leave a Reply

Close Menu